FDA Drug · D-0813-2026

CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.

Class II · Ongoing

CGMP Deviations

Affected lots / codes — check yours against thisLot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027.

Recalling firm: Baxter Healthcare Corporation, Deerfield, IL
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: N/A
Distribution: US Nationwide; Puerto Rico; and Chile.
Recall initiated: August 6, 2026
Classified: August 28, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0813-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →